MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Augmenix wins FDA nod for SpaceOar prostate treatment

Augmenix wins FDA nod for SpaceOar prostate treatment

April 3, 2015 By Mark Hollmer Leave a Comment

Share
Augmenix wins FDA nod for SpaceOar prostate treatment

FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to help protect the rectum during prostate cancer radiotherapy, CEO John Pedersen told MassDevice.com today.

“We are rolling the technology out in a responsible way, focusing on physician training,” Pedersen said in a telephone interview. “Our goal is to train 20 to 30 centers this year in using the technology.”

The Waltham, Mass.-based company this week won de novo clearance from the FDA for its SpaceOar System, which is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer. SpaceOar is delivered through a small needle as a liquid,d then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient’s urine, according to Augmenix.

Pedersen told us that obtaining reimbursement for SpaceOar could take about 2 years, noting that the company is going for a Category I CPT code because SpaceOar does not appear to fit under existing reimbursement codes options. In the interim, a reimbursement-consulting firm has advised Augmenix that while it won’t have a national coverage policy, it can rely on miscellaneous codes on a case-by-case basis. Discussions with the Centers for Medicare & Medicaid Services and private payers are ongoing, he said.

Typically, the patient population for prostate cancer is older men, with 70% falling under Medicare and the rest covered by private insurance, Pedersen said.

The SpaceOar System, which won CE Mark approval in the European Union in July 2010, is commercially available in Europe and Australia. Augmenix raised a $10.8 million Series D round last July to help support the final stages of its bid for FDA approval.

Pedersen, who joined Augmenix last December, said he brought on a sales and marketing team that is trained and “ready to go.” More than 20 people work for the company domestically; distributors are used to sell SpaceOar abroad. Founder Amar Sawhney remains as chairman (a serial entrepreneur, Sawhney is also president & CEO of Ocular Therapeutix (NSDQ:OCUL), a company he co-founded that also uses hydrogel technology).

Pedersen said that he views SpaceOar as “game-changing” because it offers a new way to treat prostate cancer with radiation without “dosing the rectum and creating unacceptable levels of rectal toxicity.”

Prostate cancer patients face limited choices, he explained: Surgery, which can cause erectile dysfunction and urinary side effects; or radiation therapy, which can leave patients with issues ranging from rectal bleeding to bowel inflammation and more.

Researchers tested the SpaceOar System in a prospective, randomized clinical trial involving 222 patients at 20 U.S. sites.* They generated a 99% success rate for gel placement, creating an average 0.5 inches of space between the prostate and rectum. Patients experienced a 74% reduction in rectal V70 radiation exposure, according to the company. This, in turn, left subjects with 76% less rectal pain during radiation treatment and 71% less rectal toxicity 15 months after treatment. Crucially, there was also a 46% reduction in patients reporting a negative impact on their bowel/quality of life 1 year after radiation treatment.

Augmenix is also developing uses for the hydrogel spacing concept in treating other cancers, Pedersen said.

*Correction, April 3, 2015: Due to a reporter’s error, this article originally mis-stated the risk and number of patients in the Augmenix clinical trial. Return to the corrected sentence.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Urology Tagged With: Augmenix Inc., De Novo Clearance, Prostate

In case you missed it

  • Judge sends ‘brain fingerprinting company’ and would-be distributor to arbitration
  • FDA gives massive Medtronic recall Class I designation
  • Affluent Medical touts results of endovascular aneurysm repair study
  • NeoTract’s UroLift system gains expanded insurance coverage
  • Innovasive rebrands as Amplify Surgical
  • Report: FDA panel wants more extensive data, quality of life outcomes for vaginal mesh products
  • These medtech companies raised the most VC in 2018
  • IEEE publishes safety standards draft for medtech interoperability
  • Senseonics partners to provide veterans with Eversense CGM
  • FDA goes after California stem cell doc for unapproved breast implant device
  • FTC wants more details on $4B Boston Scientific-BTG tie-up
  • Tandem wins interoperable claim for insulin pump from FDA
  • Nevro files patent infringement suit against Stimwave
  • A record year for device innovation
  • Soterix Medical launches tDCS trial for cocaine addiction
  • Corindus asks FDA for expanded neurosurgery indication for CorPath GRX
  • FDA green-lights early feasibility trial for Foldax’s Tria biopolymer heart valve

RSS From Medical Design & Outsourcing

  • Empowering Medical Innovation
    From faster medical device development to life-saving surgical planning models, see how full-color, multi-material 3D printing opens up broad possibilities for medical innovation. In this new E-book you’ll learn how the Stratasys J750 can: Produce superior medical models for surgical planning and training Foster better medical devices through faster ideation and prototyping Enable advanced training… […]
  • Affluent Medical touts results of endovascular aneurysm repair study
    Medtech startup Affluent Medical(Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent… […]
  • This cotton-based biofuel cell could power implanted medical devices
    Researchers at the Georgia Institute of Technology and Korea University have developed a glucose-powered biofuel cell that uses electrodes from cotton that could potentially power implantable medical devices. The fuel cell has twice as much power as traditional biofuel cells and could also be paired with batteries or super capacitors to create a hybrid power… […]
  • IEEE publishes safety standards draft for medtech interoperability
    The Institute of Electrical and Electronics Engineers (IEEE) Standards Association said it has published a draft set of standards intended to provide safe and secure medical device interoperability. IEEE 11073-20701-2018, also known as IEEE Approved Draft Standard for Service-Oriented Medical Device Exchange Architecture & Protocol Binding, completes the International Organization for Standardization (ISO)/IEEE 11073 family of standards… […]
  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively.… […]
  • ODU touts Medi-Snap Advanced plastic circular connector for medical applications
    ODU (Camarillo, Calif.) recently announced that it is introducing its Medi-Snap Advanced plastic circular connector to the North American market. ODU describes the Medi-Snap as lightweight and cost-efficient. It’s a plastic circular connector with high chemical resistance ideal for medical, industrial and test and measurement applications, according to the company. The autoclavable connector is IEC 60601-1 compliant and… […]
  • Regulatory software company Complion raises $7M
    Complion (Cleveland) — a maker of regulatory software for clinical research sites — recently announced that it has raised $7 million in its latest funding round. Beringea led the Series B round, the company announced on Feb. 12. The round ended up being oversubscribed, thanks to interest from existing investors including the Ohio Innovation Fund, JumpStart… […]
  • These new titanium strip grades could enable better neuromodulation devices
    Officials at Ametek Specialty Metal Products (Collegeville, Pa.) think their new titanium strip grades for medical applications could enable more innovation in the fast-growing neuromodulation device sector. Ametek’s Hamilton Precision Metals and SMP Wallingford businesses have proprietary production processes for the new titanium grades — grades 9 and 23. They manufacture thin strips of the titanium through cold… […]
  • CoorsTek Bioceramics touts composite ceramic material
    CoorsTek Bioceramics officials think testing and clinical feedback since 2011 has shown their CeraSurf-p alumina matrix composite ceramic material to be a state-of-the-art ceramic bearing material for total hip arthroplasty. CoorsTek’s CeraSurf-p is an implant grade alumina matrix composite ceramic material that falls under the ISO 6474-2 Type X (extra high strength) material standard. The proprietary material… […]
  • Life Spine launches sacroiliac screw study
    Life Spine (Huntley, Ill.) said it has begun a study of sacroiliac joint fixation outcomes using its SImpact screw. SImpact is a cannulated and fenestrated screw, intended for sacroiliac joint fusion for conditions including sacroiliac joint disruptions and degenerative sacroiliitis through a lateral approach. It incorporates the proprietary surface technology Osseo-Loc, and is available in… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS